Bedre og sikrere innlogging på nettsidene til Legeforeningen!

Innlogging på Legeforeningens nettsider vil erstattes med en sikrere og bedre løsning, mer informasjon kommer snart!

Den private innboksen i portalen forsvinner i løpet av kort tid. Varsel om dette ble lagt ut på meldingssiden 11. juni 2019.

LEFO - Legeforskningsinstituttet

Institute for Studies of the Medical Profession

2011

Therapeutic decisions by number needed to treat and survival gains: a cross-sectional survey of lipid-lowering drug recommendations

Halvorsen PA, Wisløff TF, Støvring H, Aasland O, Kristiansen IS. Br J Gen Pract. 2011 Aug;61(589):477-83.
6. september 2011

Article in English.

Abstract on Pubmed: BACKGROUND: Previous studies suggest that lay people have difficulties with evaluating effect size in terms of number needed to treat (NNT), but they are sensitive to effect size in terms of survival gains. AIM: To explore whether GPs and internists are sensitive to NNT and survival gains when considering a lipid-lowering drug therapy. DESIGN AND SETTING: Cross-sectional survey of primary prevention of cardiovascular disease with random allocation to different scenarios. METHOD: GPs (n = 450) and internists (n = 450) were posted a vignette presenting a high-risk patient and a novel drug, `neostatin`. The benefit was described in terms of NNT or mean gain in disease-free survival. Each physician was randomly allocated to one version of the vignette. Outcome measures were evaluation of `neostatin` on a Likert scale (0: very poor choice, 10: very good choice) and the proportion recommending `neostatin`. RESULTS: A total of 477 responses (53%) were received. Among responders to NNT scenarios, 26%, 31%, and 43% recommended `neostatin` for NNT values of 34, 17, and 9 respectively. With equivalent disease-free survival gains of 9, 17, and 32 months, 40%, 49%, and 52% respectively recommended the drug. On the rating scale, mean values were 4.7, 5.0, and 5.5 across the respective NNT scenarios and 5.2, 6.2, and 6.1 across the scenarios presenting survival gains. Differences in trends between the two formats were not statistically significant. In total, 33% recommended `neostatin` when presented with NNT values, compared to 47% when presented with survival gain (χ(2) = 9.2, P= 0.002). CONCLUSION: Physicians presented with survival gains were more likely to recommend the therapy than those presented with NNT. Sensitivity to effect size was similarfor both effect formats.